Innate and adaptive immune responses in chronic hepatitis B virus infections:Towards restoration of immune control of viral infection

Postgraduate Medical Journal

Volumn 89, Issue 1051, 2013, Pages 294-304

  Bertoletti, Antonio ^a,b,c   Ferrari, Carlo ^d  

^a AGENCY FOR SCIENCE   (Singapore)

^b DUKE NUS MEDICAL SCHOOL   (Singapore)

^c Dept Medicine Endocrinol Diabet   (Singapore)

^d UNIVERSITY HOSPITAL OF PARMA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; B7 ANTIGEN; BETA INTERFERON; CD137 ANTIGEN; CD137 LIGAND; CD3 ANTIGEN; CD4 ANTIGEN; CD40 ANTIGEN; CD8 ANTIGEN; CD86 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; HEPATITIS B (E) ANTIGEN; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; INTERFERON REGULATORY FACTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 22; INTERLEUKIN 6; INTERLEUKIN 8; NUCLEOSIDE ANALOG; PROGRAMMED DEATH 1 RECEPTOR; RETINOIC ACID INDUCIBLE PROTEIN I; STAT PROTEIN; TOLL LIKE RECEPTOR 3; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS DNA;

ADAPTIVE IMMUNITY; ARTICLE; CELL FUNCTION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HUMAN; INNATE IMMUNITY; NATURAL KILLER CELL; NONHUMAN; RECOGNITION; TH17 CELL; VIRUS REPLICATION;

EID: 84876430054     PISSN: 00325473     EISSN: 14690756     Source Type: Journal    
DOI: 10.1136/postgradmedj-2011-301073rep     Document Type: Article

References (120)

1. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006;124:783-801.
2. Bertoletti A, Maini MK, Ferrari C. The host-pathogen interaction during HBV infection: immunological controversies. Antiviral Ther 2010;15:15-24.
3. Wieland S, Chisari FV. Stealth and cunning: hepatitis B and hepatitis C viruses. J Virol 2005;79:9369-80.
4. Bertoletti A, Ferrari C. Kinetics of the immune response during HBV and HCV infection. Hepatology 2003;38:4-13.
5. Gripon P, Rumin S, Urban S, et al. Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci U S A 2002;99:15655-60.
6. Hantz O, Parent R, Durantel D, et al. Persistence of the hepatitis B virus covalently closed circular DNA in HepaRG human hepatocyte-like cells. J Gen Virol 2009;90:127-35.
7. Roggendorf M, Tolle TK. The woodchuck: an animal model for hepatitis B virus infection in man. Intervirology 1995;38:100-12.
8. Guy CS, Mulrooney-Cousins PM, Churchill ND, et al. Intrahepatic expression of genes affiliated with innate and adaptive immune responses immediately after invasion and during acute infection with woodchuck hepadnavirus. J Virol 2008;82:8579-91.
9. Dandri M, Burda MR, Torok E, et al. Repopulation of mouse liver with human hepatocytes and in vivo infection with hepatitis B virus. Hepatology 2001;33:981-8.
10. Stacey AR, Norris PJ, Qin L, et al. Induction of a striking systemic cytokine cascade prior to peak in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J Virol 2009;83:3719-33.
11. Dunn C, Peppa D, Khanna P, et al. Temporal analysis of early immune responses in patients with acute hepatitis B virus infection. Gastroenterology 2009;137:1289-300.
12. Wieland S, Thimme R, Purcell RH, et al. Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci U S A 2004;101:6669-74.
13. Su AI, Pezacki JP, Wodicka L, et al. Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci U S A 2002;99:15669-74.
14. Durantel D, Zoulim F. Innate response to hepatitis B virus infection: observations challenging the concept of a stealth virus. Hepatology 2009;50:1692-5.
15. Lucifora J, Durantel D, Testoni B, et al. Control of hepatitis B virus replication by innate response of HepaRG cells. Hepatology 2010;51:63-72.
16. Hösel M, Quasdorff M, Wiegmann K, et al. Not Interferon, but interleukin-6 controls early gene expression in hepatitis B virus infection. Hepatology 2009;50:1773-82.
17. Unterholzner L, Bowie AG. Innate DNA sensing moves to the nucleus. Cell Host Microbe 2011;9:351-3.
18. Asabe S, Wieland SF, Chattopadhyay PK, et al. The size of the viral inoculum contributes to the outcome of hepatitis B virus infection. J Virol 2009;83:9652-62.
19. Coffin CS, Michalak TI. Persistence of infectious hepadnavirus in the offspring of woodchuck mothers recovered from viral hepatitis. J Clin Invest 1999;104:203-12.
20. Lütgehetmann M, Bornscheuer T, Volz T, et al. Hepatitis B virus limits response of human hepatocytes to interferon-α in chimeric Mice. Gastroenterology 2011;140:2074-83.
21. Sharma S, Fitzgerald KA. Innate immune sensing of DNA. PLoS Pathog 2011;7:e1001310.
22. Kerur N, Veettil M, Sharma-Walia N, et al. IF I16 acts as a nuclear pathogen sensor to induce the inflammasome in response to Kaposi Sarcoma-associated herpesvirus infection. Cell Host Microbe 2011;9:363-75.
23. Wang H, Ryu WS. Hepatitis B virus polymerase blocks pattern recognition receptor signalling via interaction with DDX3: implications for immune evasion. PloS Pathog. Published Online First: 15 July 2010. doi:e1000986
24. Yu S, Chen J, Wu M, et al. Hepatitis B virus polymerase inhibits RIG-I- and Toll-like receptor 3-mediated beta interferon induction in human hepatocytes through interference with interferon regulatory factor 3 activation and dampening of the interaction between TBK1/IKKepsilon and DDX3. J Gen Virol 2010;91:2080-90.
25. Wei C, Ni C, Song T, et al. The hepatitis B virus X protein disrupts innate immunity by downregulating mitochondrial antiviral signalling protein. J Immunol 2010;185:1158-68.
26. Kumar M, Jung SY, Hodgson AJ, et al. Hepatitis B virus regulatory HBx protein binds to adaptor protein IPS-1 and inhibits the activation of beta interferon. J Virol 2011;85:987-95.
27. Wang X, Li Y, Mao A, et al. Hepatitis B virus X protein suppresses virus-triggered IRF3 activation and IFN-beta induction by disrupting the VISA-associated complex. Cell Mol Immunol 2010;7:341-8.
28. Christen V, Duong F, Bernsmeier C, et al. Inhibition of alpha interferon signaling by hepatitis B virus. J Virol 2007;81: 159-65.
29. Wu M, Xu Y, Lin S, et al. Hepatitis B virus polymerase inhibits the interferon-inducible MyD88 promoter by blocking nuclear translocation of Stat1. J Gen Virol 2007;88:3260-9.
30. Foster GR, Ackrill AM, Goldin RD, et al. Expression of the terminal protein region of hepatitis B virus inhibits cellular responses to interferons alpha and?gamma and double stranded RNA. Proc Natl Acad Sci U S A 1991;88:2888-92.
31. Sarasin-Filipowicz M, Oakeley E, Duong FH, et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A 2008;105:7034-9.
32. Bellecave P, Gouttenoire J, Gajer M, et al. Hepatitis B and C virus coinfection: a novel model system reveals the absence of direct viral interference. Hepatology 2009;50:46-55.
33. Liu CJ, Chuang WL, Lee CM, et al. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology 2009;136:496-504.
34. Wu J, Meng Z, Jiang M, et al. Hepatitis B virus suppresses tolllike receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. Hepatology 2009;49:1132-40.
35. Visvanathan K, Skinner NA, Thompson AJ, et al. Regulation of toll-like receptor-2 expression in chronic hepatitis B by the precore protein. Hepatology 2007;45:102-10.
36. Frelin L, Wahlström T, Tucker AE, et al. A mechanism to explain the selection of the hepatitis e antigen-negative mutant during chronic hepatitis B virus infection. J Virol 2009;83:1379-92.
37. Biron CA, Brossay L. NK cells and NKT cells in innate defense against viral infections. Curr Opin Immunol 2001;13:458-64.
38. Gehring A., Sun D, Kennedy PT, et al. The level of viral antigen presented by hepatocytes influences CD8 T-cell function. J Virol 2007;81:2940-9.
39. Guidotti LG, Rochford R, Chung J, et al. Viral clearance without destruction of infected cells during acute HBV infection. Science 1999;284:825-9.
40. Thimme R, Wieland S, Steiger C, et al. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 2003;77:68-76.
41. Webster G, Reignat S, Maini M, et al. Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology 2000;32:1117-24.
42. Fisicaro P, Valdatta C, Boni C, et al. Early kinetics of innate and adaptive immune responses during hepatitis B virus infection. Gut 2009;58:974-82.
43. Dunn C, Brunetto M, Reynolds G, et al. Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cellmediated liver damage. J Exp Med 2007;204:667-80.
44. Oliviero B, Varchetta S, Paudice E, et al. Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections. Gastroenterology 2009;137:1151-60.
45. Peppa D, Micco L, Javaid A, et al. Blockade of immunosuppressive cytokines restores NK cell antiviral function in chronic hepatitis B virus infection. Plos Pathog 2010;6: e1001227.
46. Zhang Z, Zhang S, Zou Z, et al. Hypercytolytic activity of hepatic natural killer cells correlates with liver injury in chronic hepatitis B patients. Hepatology 2011;53:73-85.
47. Stegmann KA, Björkström NK, Veber H, et al. Interferon-alphainduced TRAIL on natural killer cells is associated with control of hepatitis C virus infection. Gastroenterology 2010;138:1885-97.
48. Tu Z, Bozorgzadeh A, Pierce RH, et al. TLR-dependent cross talk between human Kupffer cells and NK cells. J Exp Med 2008;205:233-44.
49. Tan AT, Koh S, Goh W, et al. A longitudinal analysis of innate and adaptive immune profile during hepatic flares in chronic hepatitis B. J Hepatol 2010;52:330-9.
50. Isogawa M, Robek MD, Furuichi Y, et al. Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J Virol 2005;79:7269-72.
51. Guo H, Jiang D, Ma D, et al. Activation of pattern recognition receptor-mediated innate immunity inhibits the replication of hepatitis B virus in human hepatocyte-derived cells. J Virol 2009;83:847-58.
52. Menne S, Tennant BC, Liu KH, et al. Anti-viral efficacy and induction of an antibody response against surface antigen with the TLR7 agonist GS-9620 in the woodchuck model of chronic HBV infection. 4J Hepatol 2011;54(Suppl 1):S441. Abstract 1114.
53. Lanford RE, Guerra B, Chavez DC, et al. Therapeutic efficacy of the TLR7 agonist GS-9620 for HBV chronic infection in chimpanzees. J Hepatol 2011;54:S45.
54. Petersen J, Dandri M, Mier W, et al. Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat Biotechnol 2008;26:335-41.
55. Sastry KS, Too CT, Kaur K, et al. Targeting hepatitis B virusinfected cells with a T-cell receptor like antibody. J Virol 2011;85:1935-42.
56. Whalley SA, Murray JM, Brown D, et al. Kinetics of acute hepatitis B virus infection in humans. J Exp Med 2001;193:847-54.
57. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005;5:215-29.
58. Guidotti LG, Chisari FV. Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol 2006;1:23-61.
59. Sitia G, Iannacone M, Muller S, et al. Treatment with HMGB1 inhibitors diminishes CTL-induced liver disease in HBV transgenic mice. J Leukoc Biol 2007;81:100-7.
60. Sitia G, Isogawa M, Iannacone M, et al. MMPs are required for recruitment of antigen-nonspecific mononuclear cells into the liver by CTLs. J Clin Invest 2004;113:1158-67.
61. Iannacone M, Sitia G, Isogawa M, et al. Platelets mediate cytotoxic T lymphocyte-induced liver damage. Nat Med 2005;11:1167-9.
62. Iannacone M, Sitia G, Ruggeri ZM, et al. HBV pathogenesis in animal models: recent advances on the role of platelets. J Hepatol 2007;46:719-26.
63. Wherry EJ, Ahmed R. Memory CD8 T-cell differentiation during viral infection. J Virol 2004;78:5535-45.
64. Wherry EJ, Barber DL, Kaech SM, et al. Antigen-independent memory CD8 T cells do not develop during chronic viral infection. Proc Natl Acad Sci U S A 2004;101:16004-9.
65. Boni C, Fisicaro P, Valdatta C, et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol 2007;81:4215-25.
66. Boettler T, Panther E, Bengsch B, et al. Expression of the interleukin-7 receptor alpha chain (CD127) on virus-specific CD8+ T cells identifies functionally and phenotypically defined memory T cells during acute resolving hepatitis B virus infection. J Virol 2006;80:3532-40.
67. Sandalova E, Laccabue D, Boni C, et al. Contribution of herpesvirus specific CD8 T cells to anti-viral T cell response in humans. PLoS Pathog. Published Online First: 19 August 2011. doi:e1001051
68. Chisari FV. Regulation of human lymphocyte function by a soluble extract from normal human liver. J Immunol 1978;121:1279-86.
69. Das A, Hoare M, Davies N, et al. Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection. J Exp Med 2008;205:2111-24.
70. Marshall HD, Urban SL, Welsh RM. Virus-induced transient immune suppression and the inhibition of T cell proliferation by type I interferon. J Virol 2011;85:5929-39.
71. Webster GJ, Reignat S, Brown D, et al. Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J Virol 2004;78:5707-19.
72. Maini MK, Boni C, Lee KK, et al. The role of virus-specific CD8 cells in viral control and liver damage during persistent hepatitis B virus infection. J Exp Med 2000;191:1269-80.
73. Fisicaro P, Valdatta C, Massari M, et al. Antiviral intrahepatic T-- cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology 2010;138:682-93.
74. Bertolino P, Trescol-Biémont MC, Rabourdin-Combe C. Hepatocytes induce functional activation of naïve CD8 T lymphocytes but fail to promote survival. Eur J Immunol 1998;28:221-36.
75. Bowen DG, Zen M, Holz L, et al. The site of primary T cell activation is a determinant of the balance between intrahepatic tolerance and immunity. J Clin Invest 2004;114:701-12.
76. Crispe IN. Liver antigen presenting cells. J Hepatol 2011;54:357-65.
77. Schildberg FA, Wojtalla A, Siegmund SV, et al. Murine hepatic stellate cells Veto CD8 T cell activation by a CD54-dependent mechanism. Hepatology 2011:54:262-72.
78. Schurich A, Khanna P, Lopes AR, et al. Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-Prone CD8 T cells in persistent hepatitis B virus infection. Hepatology 2011;53:1494-50.
79. Raziorrouh B, Schraut W, Gerlach T, et al. The immunoregulatory role of CD244 in chronic hepatitis B infection and its inhibitory potential on virus-specific CD8+ T-cell function. Hepatology 2010;52:1934-47.
80. Yang PL, Althage A, Chung J, et al. Immune effectors required for hepatitis B virus clearance. Proc Natl Acad Sci U S A 2010;107:798-802.
81. O'Shea JJ, Paul E. Mechanisms underlying lineage commitment and plasticity of helper CD4+ T cells. Science 2010;327:1098-102.
82. Zenewicz LA, Yancopoulos GD, Valenzuela DM, et al. Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation. Immunity 2007;27:647-59.
83. Chiaramonte MG, Donaldson DD, Cheever AW, et al. An IL-13 inhibitor blocks the development of hepatic fibrosis during a T--helper type 2-dominated inflammatory response. J Clin Invest 1999;104:777-85.
84. Yang G, Liu A, Xie Q, et al. Association of CD4+CD25+Foxp3+ regulatory T cells with chronic activity and viral clearance in patients with hepatitis B. Int Immunol 2007;19:133-40.
85. Zhang J, Zhang Z, Lin F, et al. Interleukin-17-producing CD4(+) T cells increase with severity of liver damage in patients with chronic hepatitis B. Hepatology 2010;51:81-91.
86. Xu D, Fu J, Jin L, et al. Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J Immunol 2006;177:739-47.
87. Xiang X, Gui H, King NJ, et al. IL-22 and non-ELR-CXC chemokine expression in chronic hepatitis B virus infected liver. Immunol Cell Biol. Published Online First: 27 Sep 2011. doi:10.1038/icb.2011.79. http://www.ncbi.nlm.nih.gov/pubmed/21946664
88. Billerbeck E, Kang YH, Walker L, et al. Analysis of CD161 expression on human CD8+ T cells defines a distinct functional subset with tissue-homing properties. Proc Natl Acad Sci U S A 2010;107:3066-11.
89. Stoop JN, van der Molen RG, Baan CC, et al. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology 2005;41:771-8.
90. Franzese O, Kennedy PT, Gehring A., et al. Modulation of the CD8+-T-cell response by CD4+ CD25+ regulatory T cells in patients with hepatitis B virus infection. J Virol 2005;79:3322-8.
91. Zhang Y, Cobleigh M, Lian J, et al. A proinflammatory role for interleukin-22 in the immune response to hepatitis B virus. Gastroenterology. Published Online First: 25 June2011.doi:10.1053/j.gastro.2011.06.051
92. Gehring A, Koh S, Chia A, et al. Licensing virus-specific T cells to secrete the neutrophil attracting chemokine CXCL-8 during hepatitis B virus infection. PloS One 2011;6:23330.
93. Zimmermann HW, Seidler S, Gassler N, et al. Interleukin-8 is activated in patients with chronic liver diseases and associated with hepatic macrophage accumulation in human liver fibrosis. PLoS One 2011;6:21381.
94. Sitia G, Isogawa M, Kakimi K, et al. Depletion of neutrophils blocks the recruitment of antigen-nonspecific cells into the liver without affecting the antiviral activity of hepatitis B virus-specific cytotoxic T lymphocytes. Proc Natl Acad Sci U S A 2002;99:13717-22.
95. Wherry EJ, Blattman JN, Ahmed R. Low CD8 T-cell proliferative potential and high viral load limit the effectiveness of therapeutic vaccination. J Virol 2005;79:8960-8.
96. Abdel-Hakeem MS, Bédard N, Badr G, et al. Comparison of immune restoration in early versus late alpha interferon therapy against hepatitis C virus. J Virol 2010;84:10429-35.
97. Sprengers D, Stoop JN, Binda RS, et al. Induction of regulatory T cells and interleukin-10-producing cells in non-responders to pegylated interferon-alpha therapy for chronic hepatitis B. Antivir Ther 2007;12:1087-96.
98. Carotenuto P, Artsen A, Niesters HG, et al. In-vitro use of autologous dendritic cells improves detection of T cell responses to hepatitis B virus (HBV) antigens. J Med Virol 2009;81:332-9.
99. Carey I, D'Antiga L, Bansal S, et al. Immune and viral profile from tolerance to hepatitis B surface antigen clearance: a longitudinal study of vertically hepatitis B virus-infected children on combined therapy. J Virol 2011;85:2416-28.
100. Boni C, Bertoletti A, Penna A, et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 1998;102:968-75.
101. Boni C, Penna A, Ogg GS, et al. Lamivudine treatment can overcome cytotoxic T cell hyporesponsiveness in chronic hepatitis B: new perspective for immune therapy. Hepatology 2001;33:963-71.
102. Boni C, Penna A, Bertoletti A, et al. Transient restoration of antiviral T cell responses induced by lamivudine therapy in chronic hepatitis B. J Hepatol 2003;39:595-605.
103. Brooks DG, Trifilo MJ, Edelmann KH, et al. Interleukin-10 determines viral clearance or persistence in vivo. Nat Med 2006;12:1301-9.
104. Ejrnaes M, Filippi CM, Martinic MM, et al. Resolution of a chronic viral infection after interleukin-10 receptor blockade. J Exp Med 2006;203:2461-72.
105. Shevach EM. TGF-beta to the rescue. Immunity 2010;32:585-7.
106. Shevach EM. Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity 2009;30: 636-45.
107. Lopes AR, Kellam P, Das A, et al. Bim-mediated deletion of antigen-specific CD8 T cells in patients unable to control HBV infection. J Clin Invest 2008;118:1835-45.
108. Gehring A., Xue SA, Ho ZZ, et al. Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines. J Hepatol 2011;55:103-10.
109. Deng Q, Mancini-Bourgine M, Zhang X, et al. Hepatitis B virus as a gene delivery vector activating foreign antigenic T cell response that abrogates viral expression in mouse models. Hepatology 2009;50:1380.
110. Maini MK, Schurich A. The molecular basis of the failed immune response in chronic HBV: therapeutic implications. J Hepatol 2010;52:616-19.
111. Wang C, Lin GH, McPherson AJ, et al. Immune regulation by 4--1BB and 4-1BBL: complexities and challenges. Immunol Rev 2009;229:192-215.
112. Publicover J, Goodsell A, Nishimura S, et al. IL-21 is pivotal in determining age-dependent effectiveness of immune responses in a mouse model of human hepatitis B. J Clin Invest 2011;121:1154-62.
113. Bertoletti A, Gehring A. Therapeutic vaccination and novel strategies to treat chronic HBV infection. Expert Rev Gastroenterol Hepatol 2009;3:561-9.
114. Bohne F, Chmielewski M, Ebert G, et al. T cells redirected against hepatitis B virus surface proteins eliminate infected hepatocytes. Gastroenterology 2008;134:239-47.
115. Johnson LA, Morgan RA, Dudley ME, et al. Gene therapy with mouse and human T cell receptor mediates cancer regression and targets normal tissue expressing cognate antigens. Blood 2009;114:535.
116. Kamili S, Sozzi V, Thompson G, et al. Efficacy of hepatitis B vaccine against antiviral drug-resistant hepatitis B virus mutants in the chimpanzee model. Hepatology 2009;49:1483-91.
117. Lok AS, Liang RH, Chiu EK, et al. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991;100:182-8.
118. Caselitz M, Link H, Hein R, et al. Hepatitis B associated liver failure following bone marrow transplantation. J Hepatol 1997;27:572-7.
119. Lau GK, Liang R, Wu PC, et al. Use of famciclovir to prevent HBV reactivation in HBsAg-positive recipients after allogeneic bone marrow transplantation. J Hepatol 1998;28:359-68.
120. Shibolet O, Ilan Y, Gillis S, et al. Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood 2002;100:391-6.